PharmaCyte Biotech, Inc. $PMCB

By Microcap Ledger desk · CIK 0001157075

Facts as of Oct 11, 2026, 08:19 AM UTC. Built from SEC filings and our own data. Small caps move fast; check the latest filings.

Snapshot

Exchange: Nasdaq Capital Market
Sector: Biological Products, (No Diagnostic Substances)
Headquarters: Las Vegas, NV
Fiscal year end: April 30
Shares outstanding: 10,735,649 [10-Q 2026-09-14]
as of 2026-09-11

Sources: [10-K 2026-07-29]

What the company doesAI summary of filing

PharmaCyte Biotech is a development-stage biotechnology company focused on developing cellular therapies for cancer using its Cell-in-a-Box® live cell encapsulation technology. The company's lead product candidate, CypCaps™, encapsulates genetically engineered human cells and is intended to treat locally advanced, inoperable, non-metastatic pancreatic cancer by converting chemotherapy prodrugs into cancer-killing forms at tumor sites. The company has not generated product revenue; its IND for pancreatic cancer has been under FDA clinical hold since October 2020, and the company is currently addressing FDA-identified deficiencies in manufacturing, nonclinical data, and product characterization while its board reviews its development programs and relationship with its manufacturing partner, SG Austria. [10-K 2026-07-29]

Segments: CypCaps™ (pancreatic cancer)

Financial health

From XBRL company facts (USD)
Period	Revenue	Net income	Operating cash flow	Cash	Filing
3 months to Jul 2026	$0.00	−$5.08M	−$780.9K	$17.74M	[10-Q 2026-09-14]
FY ended Apr 2026	$0.00	−$19.42M	−$5.15M	$18.60M	[10-K 2026-07-29]
FY ended Apr 2025	$0.00	$30.66M	−$2.98M	$15.17M	[10-K 2026-07-29]

Quarterly cash burn: −$780.9K

Capital structure and dilution

Summary only. How these instruments work: Dilution & financing desk.

Share count
Date	Shares outstanding	Filing
2024-12-09	6,968,134	[10-Q 2024-12-13]
2025-03-07	6,863,699	[10-Q 2025-03-17]
2025-08-04	6,795,779	[10-K 2025-08-11]
2025-09-12	6,795,779	[10-Q 2025-09-15]
2025-12-16	10,134,160	[10-Q 2025-12-18]
2026-03-12	10,735,649	[10-Q 2026-03-17]
2026-07-24	10,735,649	[10-K 2026-07-29]
2026-09-11	10,735,649	[10-Q 2026-09-14]

Shelf registration: S-3 filed 2025-09-17; declared effective 2025-09-26 [S-3 2025-09-17]

Listing status

Current status: 1 Form 8-K Item 3.01 filing(s) in the last 24 months, most recent 2025-12-05. Item 3.01 covers delisting notices, failures to meet a listing rule and listing transfers; read the filing for which one.

Date	Event	Details	Deadline	Filing
2025-12-05	8-K Item 3.01	Notice of delisting or failure to satisfy a continued listing rule or standard; or transfer of listing	—	[8-K 2025-12-05]

More on deficiency notices and uplistings: Listing status desk.

Who owns it

Recent Form 4 transactions
Date	Insider	Type	Shares	Price	Filing
2026-01-07	Silverman Joshua	buy	40,000	$0.83	[4 2026-01-07]
2026-01-07	Schechter Jonathan	buy	20,000	$0.84	[4 2026-01-07]
2026-01-06	Silverman Joshua	buy	30,000	$0.79	[4 2026-01-07]
2026-01-06	Schechter Jonathan	buy	20,000	$0.79	[4 2026-01-07]
2026-01-05	Silverman Joshua	buy	30,000	$0.78	[4 2026-01-07]
2026-01-05	Schechter Jonathan	buy	20,000	$0.78	[4 2026-01-07]
2025-12-12	Weinstein Robert	grant	75,000	—	[4 2025-12-12]
2025-12-12	Weinstein Robert	other	33,750	$1.02	[4 2025-12-12]

Catalysts and calendar

Recent filings and releases
Date	Type	Title
2026-09-14	10-Q	Quarterly report
2026-07-29	10-K	Annual report
2026-04-02	8-K	Director or officer change; Shareholder vote results
2026-03-18	13G	Beneficial ownership report (5%+ holder)
2026-03-17	10-Q	Quarterly report
2026-03-09	DEF 14A	Proxy statement
2026-02-27	PRE 14A	Proxy statement
2026-02-13	13G/A	Beneficial ownership report (5%+ holder)
2025-12-18	10-Q	Quarterly report
2025-12-15	NT 10-Q	Notice of late quarterly report
2025-12-05	8-K	Listing notice or transfer
2025-11-18	13D/A	Beneficial ownership report (5%+ holder)

Facts as of Oct 11, 2026, 08:19 AM UTC. Small caps move fast; check the latest filings.